Abcam, Molecular Devices join forces to develop immunoassays for researchers

Abcam and Molecular Devices combine their technologies in a series of high-sensitivity fluorescent ELISA kits for researchers.

Abcam, a supplier of protein research material and kits, has teamed up with bioanalytical measurement solutions expert Molecular Devices to develop screening tools for the life science industry.

The initial focus of this transatlantic collaboration is on creating new high-sensitivity fluorescent enzyme-linked immunosorbent assay (ELISA) kits. These immunoassays are used to detect and quantify substances such as peptides and proteins in basic research, high throughput screening and diagnostics.

The final product, called CatchPoint SimpleStep ELISA kits, combines the speed of Adcam’s single-wash protocol that reduces assay time to 90 minutes or less with Molecular Devices’ fluorescent technology. Compared to TMB substrate, using a fluorescent substrate offers “improved linearity over an extended dynamic range [that provides] better quantification at both the lower and the upper end of the curve,” described Abcam on its website.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Optimized for our industry-leading plate readers, these kits will provide customers with a cohesive solution that enables better results faster,” said Scott Greenstone, Molecular Devices’ director of open innovation and reagents, in a statement.

These combined kits are sold by U.K.-based Abcam, and Greestone said the two companies will work together throughout 2018 to further expand the offering.

A November 2016 report by Markets and Markets predicted that the global immunoassay market—including for research and diagnostic purposes—will grow from about $17 billion to over $25 billion by 2021, with hospitals accounting for the largest share.


Suggested Articles

Parexel shut down a San Diego office back in April as three workers were axed and 37 others were offered work-from-home jobs.

Charles River has penned “early 2020” for the opening of its Charles River Accelerator and Development Lab (aka CRADL) in South San Francisco.

Dialysis giant Fresenius Medical Care announced plans to expand and elevate its North America-centric Frenova research subsidiary on the global stage.